Adrenocortical Carcinoma (Part G) clinical trials at UCSD
1 research study open to new patients
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
open to eligible people ages 18 years and up
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
San Diego, California and other locations